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TSPY is a cancer testis antigen expressed in human hepatocellular
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In search for genes associated with hepatocellular carcinoma (HCC) by cDNA microarray, we found that the transcription of TSPY,
‘testis-specific protein Y-encoded’, was upregulated in HCC. Investigation of a broad spectrum of normal and malignant tissues by
RT–PCR revealed the TSPY transcript selectively expressed in normal testis, different histological types of human neoplastic tissues,
and tumour cell lines. The expression of TSPY in cancer cells was further confirmed by in situ hybridisation. Indirect
immunofluorescence microscopy analysis showed that TSPY was localised mainly in the cytoplasm of transiently transfected cells.
Testis-specific protein Y-encoded was detected in 50% (16 of 32) of well- and moderately differentiated HCC patients, in 16% (four
of 25) of poorly differentiated HCC patients, and in 5% (one of 19) of renal cell cancer patients. A serological survey revealed that
6.6% (seven of 106) HCC patients had anti-TSPY antibody response, demonstrating the immunogenicity of TSPY in humans. In
conclusion, these data suggest that TSPY is a novel cancer/testis (CT) antigen and may be a potential candidate in vaccine strategy for
immunotherapy in HCC patients.
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Hepatocellular carcinoma (HCC), the major type of primary liver
cancer, is one of the most prevalent cancers worldwide, and is
markedly increasing in incidence because of the dissemination of
hepatitis B and C virus infection (Llovet et al, 2003). Despite the
remarkable advances in diagnostic and therapeutic techniques,
prognosis of HCC still remains extremely poor ranking as the third
highest cause of cancer death (Butterfield and Ribas, 2002).
Therefore, the innovative and potentially disease-specific therapies
for HCC are of great concern. Antigen-specific immunotherapy, as
an alternative approach for treatment of HCC, is attractive due to
the exquisite specificity of the immune response. Recent reports
indicated that a subset of immunotherapy trials for HCC had
shown clinical effects (Iwashita et al, 2003; Butterfield, 2004; Kuang
et al, 2004). A prerequisite for a broad application of antigen-
specific immunotherapy is the identification of appropriate target
antigens capable of inducing an immune response. The discovery
of cancer/testis (CT) antigens, which express in a broad spectrum
of neoplasms but not in normal tissues except in testis and
placenta, has provided new perspectives for antigen-specific
immunotherapy (Scanlan et al, 2002). To date, 44 CT gene families
have been identified, and the protein products of 19 gene families
have been demonstrated to elicit immune responses in human
(Scanlan et al, 2004). The immunogenicity and restricted expres-
sion of CT antigens make them ideal candidates for specific cancer
immunity. However, the known CT antigens are expressed in only
a fraction of cases of a given tumour type, and the progressive loss
of tumour antigens is due to the immunoselection in the course of
vaccination, the identification of additional CT antigens is urgently
needed for developing polyvalent tumour vaccines to improve the
efficacy of immunotherapy (Kalos, 2003).
Recent development of cDNA microarray technology has
opened a new era in medical sciences. Several studies demon-
strated the usefulness of this technique for identifying novel
cancer-related genes and for disclosing genetic mechanisms in
cancers (Okabe et al, 2001; Iizuka et al, 2002; Smith et al, 2003).
We have performed cDNA microarray analysis for mining
differentially expressed genes during the progress of HCC in an
attempt to provide clues for identifying new therapeutic targets
(Shi et al, 2005). In this study, we identified TSPY, ‘testis-specific
protein Y-encoded’, which was overexpressed in human HCC, as
based on cDNA microarray data. We examined TSPY mRNA
expression in tumours of different histological types and the
seroreactivity against TSPY in HCC patients, suggesting that TSPY
is a novel CT antigen capable of eliciting antibody response in
HCC patients. Testis-specific protein Y-encoded may provide a
novel therapeutic target for immunotherapy in HCC patients.
MATERIALS AND METHODS
Tissues, sera, and cell lines
Tumour tissues, paired noncancerous tissues, and serum samples
were obtained with informed consent from patients who under-
went surgical resection at the 2nd School of Clinical Medicine,
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sPeking University Health Science Center, China. All the samples
are from male patients. Tissues destined for RNA extraction were
kept frozen in liquid nitrogen immediately after separation. Tissue
samples for in situ hybridisation were fixed in 4% formalin
solution and embedded in paraffin. Serum samples were stored at
 701C freezer.
Hepatocellular carcinoma cell lines (HLE: nondifferentiated,
derived from a 68-year-old male patient; Hep3B: well differentiated
(WD), derived from 8-year-old male patient) and COS7 cells were
obtained from Shanghai Institute of Cell Biology, Chinese
Academy of Sciences (Shanghai, People’s Republic of China).
The other six moderately to poorly differentiated (PD) HCC cell
lines of male origin, Hep-hcc-1, Hep-hcc-2, Hep-hcc-3, Hep-hcc-4,
Hep-hcc-5, and Hep-hcc-6, are the gifts kindly given by Professor
Ya-Jun Guo, the Second Military Medical University, China. The
cDNA of melanoma (derived from male), lung (derived from
male), breast, pancreas, colon (derived from female), prostate, and
ovary cell lines were purchased from Clontech Laboratories Inc.
(Palo Alto, CA, USA).
RT–PCR
The expression pattern of TSPY transcript was determined by RT–
PCR. In all, 16 different normal tissue cDNA preparations,
including heart (pooled from three male Caucasians), brain
(pooled from two male Caucasians), placenta, lung (pooled from
two female Caucasians), liver (pooled from three male Caucasians),
skeletal muscle (pooled from eight male/female Caucasians),
kidney (pooled from five male/female Caucasians), pancreas
(pooled from 15 male/female Caucasians), spleen (pooled from
three male/female Caucasians), thymus (pooled from 18 male/
female Caucasians), prostate, testis, ovary, small intestine (pooled
from 32 male/female Caucasians), colon (pooled from 20 male/
female Caucasians), and peripheral blood leucocyte (pooled from
550 male/female Caucasians), were purchased from Clontech
Laboratories Inc. (Palo Alto, CA, USA). RNA samples extracted
from tumour tissues, paired adjacent nontumour tissues, and cell
lines were reversely transcribed with advantage reverse transcrip-
tase (Clontech, Palo Alto, CA, USA). PCR primers specific for
amplifying TSPY transcript were: forward, 50-CAGGGCTTCT
CATTCCACTC-30; and reverse, 50-CCATCATATTCAACTCAA
CAACTGG-30. PCR was performed with 32 cycles of 20s at 941C,
20s at 581C, and 20s at 721C, followed by 7min at 721C. The
amplified products were analysed on 2% agarose/Tris-acetate-
EDTA gels stained with ethidium bromide. The integrity and
quantity of the cDNA were evaluated by amplification of
glyceraldehyde-3-phosphate dehydrogenase (G3PDH).
In situ hybridisation
Sense and antisense probes were synthesised using T7 or SP6 with
a DIG labelling kit (Roche Diagnostics, Switzerland) to generate
TSPY-labelled riboprobes. The tissue sections (5mm) were
deparaffinised, rehydrated, and incubated in 0.2 M HCl for
20min. After washing with PBS, the tissues were treated with
proteinase K at a concentration of 20mgml
 1 for 15min at 371C.
After fixation with 4% paraformaldehyde for 5min and washing in
PBS, the sections were prehybridised for 1h at 501C in a buffer
containing 50% (vv
 1) formamide, 4 SSC, 2 Denhardts solu-
tion, and 250mgml
 1 RNA. Hybridisation was performed over-
night at the same temperature in 50% (vv
 1) formamide, 4 SSC,
2 Denhardts solution, 500mgml
 1 RNA, 10% dextran sulphate,
and 2mgml
 1 DIG-labelled probes. Excess probes were removed
by washing with 2 SSC containing 50% formamide followed by
RNase (250mgml
 1) treatment at 371C for 30min. Tissues were
washed at 371Ci n2 SSC and 0.2 SSC. Then, the sections were
incubated with alkaline phosphatase (AP)-conjugated anti-DIG Ab
(Roche). Colour development was processed with nitroblue
tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate.
Cell transfection and immunofluorescence
For localisation studies, we constructed the expression plasmid
pcDNA-TSPY-FLAG by cloning a fragment containing the full-
length ORF minus the termination codon in the HindIII–BamHI
sites of pcDNA-FLAG vector. The in-frame junction was confirmed
by sequencing. COS7 cells were transfected with either vector alone
as a control or vector with TSPY insert, using LipofectAMINE 2000
(Invitrogen, CA, USA), following the manufacturer’s instructions.
After incubation at 371C for 24h, cells were fixed with precooled
100% methanol at  201C for 15min. The fixed cells were blocked
with 1% nonfat milk in PBS for 1h and stained with anti-FLAG M2
mouse monoclonal antibody (mAb) (Sigma, USA) for 1h at room
temperature (RT), followed by incubation with TRITC (tetra-
methylrhodamine isothiocyanate)-conjugated anti-mouse immu-
noglobulin G antibody (IgG Ab) for 1h at RT, and then cell nuclei
were stained with Hoechst33342 for 10min at 371C. Images were
obtained using a fluorescence microscope equipped with a Charge
Couple Device camera.
Western blot analysis
At 24h after transfection, cultured cells were lysed in 2 SDS
sample buffer (0.1 M Tris-HCl, pH 6.8/0.2 M DTT/4% SDS/0.2%
bromophenol blue/20% glycerol), and then separated by 12.5%
SDS–polyacrylamide gel electrophoresis, followed by transfer to
nitrocellulose membranes. After blocking in TNT solution contain-
ing 5% nonfat milk, the membrane was incubated with anti-FLAG
mAb (Sigma) at RT for 1h, followed by incubation with a
horseradish peroxidase-linked goat anti-mouse IgG at RT for 1h.
Colour development was performed through incubation with 3,30-
diaminobenzidine tetrahydrochloride in 0.03% H2O2 and 50mM
Tris-HCl, pH 7.4.
Seroreactivity analysis of TSPY
To analyse the presence of anti-TSPY Ab in HCC patient’s sera, the
full-length TSPY cDNA was cloned in the expression vector
pET28a (þ), and recombinant TSPY protein was produced in
Escherichia coli with the induction of 1mM IPTG at 421C for 6h.
After purification by Ni
2þ affinity chromatography, the recombi-
nant TSPY protein fused with 6 His tag was separated on 12.5%
SDS–polyacrylamide gel electrophoresis, followed by transfer to
nitrocellulose membrane. After blocking in TNT solution contain-
ing 5% nonfat milk, the membranes were incubated with sera from
HCC patients at a 1:100 dilution for 1.5h, and then with AP-
conjugated goat anti-human IgG (Promega, USA). Serum IgG
reactivity was detected with the AP substrate, 4-nitroblue
tetrazolium chloride/5-bromo-4-chloro-3-indolylphosphate. Anti-
His antibody (Qiagen) at a 1:5000 dilution was used for positive
control.
RESULTS
Expression of TSPY mRNA in normal and tumour tissues
To examine the distribution of TSPY gene expression, RT–PCR
was performed using cDNA reversed from mRNA of normal
tissues, tumours, and cancer cell lines. Testis-specific protein Y-
encoded mRNA was restricted to testis and was not detected in the
various normal tissues tested, including liver, spleen, prostate,
pancreas, ovary, colon, small intestine, heart, lung, peripheral
blood leucocyte, brain, kidney, placenta, skeletal muscle, and
thymus (Figure 1A). As the lung cDNA obtained from Clontech
was of female origin, TSPY expression was further measured in
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snormal lung tissues we collected from male patients and there was
no detectable TSPY transcript. In addition, a number of tumours of
various histological types expressed TSPY (Table 1). The TSPY was
expressed in 35.1% (20 of 57) of HCC samples (Figure 1B). A less
frequent expression was detected in renal cell cancer (one of 19).
However, no expression was found in gastric cancer, lung cancer,
bladder cancer and leukaemia samples. Histopathological diag-
nosis showed that, of the 57 HCC samples, 15 were WD, 17 were
moderately differentiated (MD), and 25 were PD. The positive
frequency of TSPY mRNA was 50% (16 of 32) in WD and MD, and
16% (four of 25) in PD HCC tissue samples. The expression of
TSPY mRNA was in the HCC cells as demonstrated by in situ
hybridisation analysis (Figure 2).
Of the eight HCC cell lines tested (HLE, Hep3B, hep-hcc-1, hep-
hcc-2, hep-hcc-3, hep-hcc-4, hep-hcc-5, hep-hcc-6), TSPY mRNA
was detected in hep-hcc-1 and hep-hcc-4 cell lines (Figure 1C).
Among other nine cancer cell lines tested, including melanoma,
ME235; lung, LX-1 and G1-117; breast, G1-101; pancreas, G1-103;
colon, CX-1 and G1-112; prostate, PC3; and ovary, G1-102, TSPY
was only expressed in melanoma cell line ME235.
Subcellular localisation of TSPY
To determine the subcellular localisation of TSPY, indirect
immunofluorescence for tagged TSPY was performed. FLAG-
tagged TSPY expression plasmid was transfected into COS7 cells.
Indirect immunofluorescence assay with anti-FLAG Ab demon-
strated that FLAG-tagged TSPY was mainly in the cytoplasm of
transfected COS7 cells (Figure 3). Testis-specific protein Y-
encoded protein was also detected by Western blot in COS7 cells
transiently transfected with pcDNA-TSPY-FLAG plasmid using
anti-FLAG Ab, the molecular weight is approximately 48kDa.
Survey of anti-TSPY seroreactivity in HCC patients
To get an impression of the frequency of anti-TSPY antibodies, the
sera of 106 HCC patients and 46 healthy controls were tested for
Ab reactivity against recombinant TSPY by Western blot (Figure 4).
B
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Figure 1 Expression of TSPY mRNA in normal and malignant tissues.
Testis-specific protein Y-encoded mRNA expression was analysed by RT–
PCR. (A) TSPY mRNA was expressed only in normal testis but not in other
tissues. Lane 1: brain; 2: heart; 3: kidney; 4: liver; 5: lung; 6: pancreas; 7:
skeletal muscle; 8: placenta; 9: ovary; 10: thymus; 11: prostate; 12: spleen;
13: testis; 14: small intestine; 15: colon; 16: leucocytes; 17: negative control;
18: positive control (testis as a positive control). (B) Expression of TSPY
mRNA in HCC tissues. Representative expression pattern is shown in
some HCC samples; testis mRNA was used as a positive control. RT–PCR
for G3PDH was used to monitor the quality of the RNA sample. (T:
cancerous tissues; N: adjacent noncancerous tissues; P: positive control).
(C) Expression of TSPY mRNA in HCC cell lines. Lane 1: hep-hcc-1; lane 2:
hep-hcc-2; lane 3: hep-hcc-3; lane 4: hep-hcc-4; lane 5: hep-hcc-5; lane 6:
hep-hcc-6; lane 7: HLE; lane 8: Hep3B; P: positive control (testis as a
positive control). RT–PCR for G3PDH was used to monitor the quality of
the RNA sample.
Table 1 Expression of TSPY transcript in malignant tissues
Tumour type TSPY expression, no. positive/no. tested
HCC 20/57
Renal cell carcinoma 1/19
Lung carcinoma NSCLC 0/13
Bladder cancer 0/8
Lymphoma or leukaemia 0/11
Gastric carcinoma 0/10
TSPY¼testis-specific protein Y-encoded; HCC¼hepatocellular carcinoma;
NSCLC¼non-small-cell lung carcinoma
Figure 2 In situ hybridisation of TSPY mRNA. In situ hybridizstion was
performed on human HCC tissues with an antisense or sense
oligonucleotide probe against TSPY mRNA. (A) HCC tissue with antisense
probe. (B) HCC tissue with sense probe as a control.
An antibody-eliciting novel CT antigen identified in HCC
Y-H Yin et al
460
British Journal of Cancer (2005) 93(4), 458–463 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sSeven HCC patients had serum Ab responses specific to
recombinant TSPY protein (6.6%), whereas all the healthy controls
were negative.
DISCUSSION
A prerequisite for a broad application of antigen-based vaccine for
immunotherapy is the identification of a wide spectrum of
immunogenic tumour antigens expressed predominately in human
cancers (Kalos, 2003; Scanlan et al, 2004). Cancer/testis antigens
are attractive targets in immunotherapy for their limited expres-
sion in normal tissue of testis, an immunological privileged site
unable to provoke immune responses. To date, 44 CT gene families
have been identified; however, the protein products of only three
gene families have been found to induce coordinated humoral and
cellular responses, including NY-ESO-1, MAGE-A, and SSX
antigens (Scanlan et al, 2004). Some preliminary results have been
reported for immunotherapy with MAGE-derived peptides (Marc-
hand et al, 1995; Toungouz et al, 2001) and NY-ESO-1 peptide or
protein (Jager et al, 2000; Chen et al, 2004; Davis et al, 2004). In
this study, we have demonstrated that TSPY is a novel CT antigen.
Our examination of TSPY mRNA expression pattern has
confirmed previous reports (Zhang et al, 1992; Schnieders et al,
1996) that human TSPY was not expressed in normal tissues except
for testis. Importantly, we found the TSPY transcript was
selectively expressed in different histological human tumours
and tumour cell lines with the dominant expression in HCC. Since
TSPY mRNA was reported to be sequence diversity, direct
sequencing of cDNAs prepared from HCC and testicular tissues
has been performed. Testis-specific protein Y-encoded transcript
from HCC was found to be identical to that from testis, and both
belong to TSPY major type encoding a protein of 308 amino acids
as identified by Schnieders et al (1996). The expression profile of
TSPY in normal tissues, tumour samples and tumour cell lines has
categorised this gene in the group of CT antigens. Testis-specific
protein Y-encoded differs from the known CT antigens by its
chromosomal localisation. Most of the hitherto known CT antigens
have been mapped to the X chromosome with the exception of a
few CT antigens that have been mapped to autosome (Scanlan
et al, 2002; Lee et al, 2003; Loriot et al, 2003). Testis-specific
protein Y-encoded gene was located on human proximal Yp,
within the GBY (gonadoblastoma locus on the Y chromosome)
critical region (Lau et al, 2000). Since HCC is three to four times
more often in men than women (Kew, 2002; El-Serag, 2004), the
relatively high frequency of TSPY in HCC patients might be of
significance in aetiology and therapeutics.
The biological function of most CT antigens is unclear except for
a few CT antigens, such as SCP-1, which is involved in meiotic
chromosome pairing (Tureci et al, 1998); OY-TES-1, involved in
the packaging of acrosin in the sperm head (Baba et al, 1994);
Figure 3 Subcellular localisation of TSPY protein. COS7 cells were
transfected with pcDNA-TSPY-FLAG for 24h, the expressed protein was
then detected. (A) TSPY protein was mostly distributed in the cytoplasm
as detected by immunofluorescence. (B) Nuclei stained with
Hoechst33342. (C) Merged images of (A) and (B).
M P123456789 1 0
61.3 KDa
49.0 KDa
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24.7 KDa
Figure 4 Serological reactivity of the recombinant TSPY protein in HCC
patients. The antibody in serum samples was assessed by Western blot
assay. M: protein marker; P: positive control; lanes 1 and 2: negative
controls with normal sera; lanes 3, 5, and 9: positive reaction with sera from
HCC patients; lanes 4, 6–8, and 10: negative reaction with sera from HCC
patients.
An antibody-eliciting novel CT antigen identified in HCC
Y-H Yin et al
461
British Journal of Cancer (2005) 93(4), 458–463 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sCT15/fertilin b, involved in egg/sperm membrane interactions
(Vidaeus et al, 1997; Primakoff and Myles, 2000); SSX, reported to
have a transcription-repressor function (Brett et al, 1997). Testis-
specific protein Y-encoded is evolutionarily conserved on the
mammalian Y chromosome, its homologous gene families have
been found in great apes (Kim and Takenaka, 1996), cattle (Vogel
et al, 1997), monkey (Kim et al, 1997), and other mammal (Lau,
1999). These suggest that TSPY might be an important gene acting
in male germ cell generation. Testis-specific protein Y-encoded has
been indeed reported to function in early spermatogenesis,
immediately prior to the spermatogonia to spermatocyte transition
(Schnieders et al, 1996). Detailed database and sequence analysis
suggest that TSPY belongs to a superprotein family, which includes
the proto-oncogene SET and the nucleosome-assembly factor
NAP-1, both interact specifically with mitotic cyclin B and are
suggested to play a role in DNA replication (Schnieders et al,
1996). SET has been identified as a potent inhibitor of protein
phosphatase 2A, a major mammalian protein serine threonine
phosphatase that regulates diverse cellular processes (Li et al,
1996). Recently, SET was found to be an inhibitor of tumour
suppressor gene NM-23H1 (Fan et al, 2003), and involved in
Galpha(12)-mediated signalling pathways (Kumar et al, 2004). In
addition, NAP-1 is needed in a transcriptional activation in
cooperation with p300 (Asahara et al, 2002). Advances in the
characterisation of SET/NAP functions may provide some
important clues to the biological role of the TSPY gene not only
in spermatogenesis but also in hepatocarcinogenesis.
In this study, the expression of TSPY mRNA in HCC
was relevant to tumour differentiation status. Testis-specific
protein Y-encoded was expressed at high proportion (50%) in
WD HCC and relatively small proportion (16%) in PD HCC. It is
well known that the HCC often shows dedifferentiation from WD
HCC to PD HCC during multistep progression (Mise et al, 1998;
Sakamoto et al, 1991). The different expression frequencies of
TSPY transcript in WD and PD, together with the structure
relationship of TSPY to SET and NAP, suggests that TSPY possibly
involve in hepatocarcinogenesis and reversely involve in progres-
sion of HCC.
A serological survey has shown that seven of 106 HCC patients
exhibited spontaneous humoral immune response to TSPY.
Although the frequency of Ab response in HCC patients is low
as most of the other CT antigens, the TSPY in vivo is
immunogenic. Further investigation on the TSPY-mediated T-cell
immune response is in process. The restricted expression in
tumours and testis and its immunogenicity imply that TSPY is a
potential vaccine candidate for immunotherapy in HCC.
ACKNOWLEDGEMENTS
This work was supported by grants from Ludwig Institute for
Cancer Research (KSP 003), China National 863 Program
(2003AA215110), and Beijing Municipal Government Foundation
for National Sciences (7001002).
REFERENCES
Asahara H, Tartare-Deckert S, Nakagawa T, Ikehara T, Hirose F, Hunter T,
Ito T, Montminy M (2002) Dual roles of p300 in chromatin assembly and
transcriptional activation in cooperation with nucleosome assembly
protein 1 in vitro. Mol Cell Biol 22: 2974–2983
Baba T, Niida Y, Michikawa Y, Kashiwabara S, Kodaira K, Takenaka M,
Kohno N, Gerton GL, Arai Y (1994) An acrosomal protein, sp32, in
mammalian sperm is a binding protein specific for two proacrosins and
an acrosin intermediate. J Biol Chem 269: 10133–10140
Brett D, Whitehouse S, Antonson P, Shipley J, Cooper C, Goodwin G (1997)
The SYT protein involved in the t(X;18) synovial sarcoma translocation
is a transcriptional activator localised in nuclear bodies. Hum Mol Genet
6: 1559–1564
Butterfield LH (2004) Immunotherapeutic strategies for hepatocellular
carcinoma. Gastroenterology 127: S232–S241
Butterfield LH, Ribas A (2002) Immunotherapy of hepatocellular carcino-
ma. Expert Opin Biol Ther 2: 123–133
Chen Q, Jackson H, Parente P, Luke T, Rizkalla M, Tai TY, Zhu HC, Mifsud
NA, Dimopoulos N, Masterman KA, Hopkins W, Goldie H, Maraskovsky
E, Green S, Miloradovic L, McCluskey J, Old LJ, Davis ID, Cebon J, Chen
W (2004) Immunodominant CD4+ responses identified in a patient
vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX
adjuvant. Proc Natl Acad Sci USA 101: 9363–9368
Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen
Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E,
McArthur G, MacGregor D, Sturrock S, Tai TY, Green S, Cuthbertson A,
Maher D, Miloradovic L, Mitchell SV, Ritter G, Jungbluth AA, Chen YT,
Gnjatic S, Hoffman EW, Old LJ, Cebon JS (2004) Recombinant NY-ESO-1
protein with ISCOMATRIX adjuvant induces broad integrated antibody
and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci
USA 101: 10697–10702
El-Serag HB (2004) Hepatocellular carcinoma: recent trends in the United
States. Gastroenterology 127: S27–S34
Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J (2003) Tumor
suppressor NM23-H1 is a granzyme A-activated DNase during CTL-
mediated apoptosis, and the nucleosome assembly protein SET is its
inhibitor. Cell 112: 659–672
Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T, Takemoto
N, Tangoku A, Hamada K, Nakayama H, Miyamoto T, Uchimura S,
Hamamoto Y (2002) Comparison of gene expression profiles between
hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma
by oligonucleotide microarray data on the basis of a supervised learning
method. Cancer Res 62: 3939–3944
Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, Chen CL, Kawano K,
Kitano S (2003) A phase I study of autologous dendritic cell-based
immunotherapy for patients with unresectable primary liver cancer.
Cancer Immunol Immunother 52: 155–161
Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A,
Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A
(2000) Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte
and antibody responses in peptide-vaccinated patients with NY-ESO-1+
cancers. Proc Natl Acad Sci USA 97: 12198–12203
Kalos M (2003) Tumor antigen-specific T cells and cancer immunotherapy:
current issues and future prospects. Vaccine 21: 781–786
Kew MC (2002) Epidemiology of hepatocellular carcinoma. Toxicology
181–182: 35–38
Kim HS, Kageyama T, Nakamura S, Takenaka O (1997) Nucleotide
sequence of cDNA and the gene expression of testis-specific protein Y in
the Japanese monkey. Zool Sci 14: 609–614
Kim HS, Takenaka O (1996) A comparison of TSPY genes from Y-
chromosomal DNA of the great apes and humans: sequence, evolution,
and phylogeny. Am J Phys Anthropol 100: 301–309
Kuang M, Peng BG, Lu MD, Liang LJ, Huang JF, He Q, Hua YP,
Totsuka S, Liu SQ, Leong KW, Ohno T (2004) Phase II randomized
trial of autologous formalin-fixed tumor vaccine for post-
surgical recurrence of hepatocellular carcinoma. Clin Cancer Res 10:
1574–1579
Kumar RN, Radhakrishnan R, Ha JH, Dhanasekaran N (2004) Proteome
analysis of NIH3T3 cells transformed by activated Galpha12: regulation
of leukemia-associated protein SET. J Proteome Res 3: 1177–1183
Lau Y, Chou P, Iezzoni J, Alonzo J, Komuves L (2000) Expression of a
candidate gene for the gonadoblastoma locus in gonadoblastoma and
testicular seminoma. Cytogenet Cell Genet 91: 160–164
Lau YF (1999) Gonadoblastoma, testicular and prostate cancers, and the
TSPY gene. Am J Hum Genet 64: 921–927
Lee SY, Obata Y, Yoshida M, Stockert E, Williamson B, Jungbluth AA, Chen
YT, Old LJ, Scanlan MJ (2003) Immunomic analysis of human sarcoma.
Proc Natl Acad Sci USA 100: 2651–2656
Li M, Makkinje A, Damuni Z (1996) The myeloid leukemia-associated
protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem
271: 11059–11062
An antibody-eliciting novel CT antigen identified in HCC
Y-H Yin et al
462
British Journal of Cancer (2005) 93(4), 458–463 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sLlovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet
362: 1907–1917
Loriot A, Boon T, De Smet C (2003) Five new human cancer-germline genes
identified among 12 genes expressed in spermatogonia. Int J Cancer 105:
371–376
Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G,
Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon JL, Laurent C,
Naeyaert JM, Plagne R, Deraemaeker R, Knuth A, Jager E, Brasseur F,
Herman J, Coulle PG, Boon T (1995) Tumor regression responses in
melanoma patients treated with a peptide encoded by gene MAGE-3. Int J
Cancer 63: 883–885
Mise K, Tashiro S, Yogita S, Wada D, Harada M, Fukuda Y, Miyake H,
Isikawa M, Izumi K, Sano N (1998) Assessment of the biological
malignancy of hepatocellular carcinoma: relationship to clinicopatholo-
gical factors and prognosis. Clin Cancer Res 4: 1475–1482
Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda
T, Furukawa Y, Nakamura Y (2001) Genome-wide analysis of gene
expression in human hepatocellular carcinomas using cDNA microarray:
identification of genes involved in viral carcinogenesis and tumor
progression. Cancer Res 61: 2129–2137
Primakoff P, Myles DG (2000) The ADAM gene family: surface proteins
with adhesion and protease activity. Trends Genet 16: 83–87
Sakamoto M, Hirohashi S, Shimosato Y (1991) Early stages of multistep
hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular
carcinoma. Hum Pathol 22: 172–178
Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer/testis
antigens: an expanding family of targets for cancer immunotherapy.
Immunol Rev 188: 22–32
Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: review,
standardization, and commentary. Cancer Immun 4: 1
Schnieders F, Dork T, Arnemann J, Vogel T, Werner M, Schmidtke J (1996)
Testis-specific protein, Y-encoded (TSPY) expression in testicular
tissues. Hum Mol Genet 5: 1801–1807
Shi YY, Wang HC, Yin YH, Sun WS, Li Y, Zhang CQ, Wang Y,
Wang S, Chen WF (2005) Identification and analysis of
tumour-associated antigens in hepatocellular carcinoma. Br J Cancer
92: 929–934
Smith MW, Yue ZN, Geiss GK, Sadovnikova NY, Carter VS, Boix L, Lazaro
CA, Rosenberg GB, Bumgarner RE, Fausto N, Bruix J, Katze MG (2003)
Identification of novel tumor markers in hepatitis C virus-associated
hepatocellular carcinoma. Cancer Res 63: 859–864
Toungouz M, Libin M, Bulte F, Faid L, Lehmann F, Duriau D, Laporte M,
Gangji D, Bruyns C, Lambermont M, Goldman M, Velu T
(2001) Transient expansion of peptide-specific lymphocytes producing
IFN-gamma after vaccination with dendritic cells pulsed with MAGE
peptides in patients with mage-A1/A3-positive tumors. J Leukocyte Biol
69: 937–943
Tureci O, Sahin U, Zwick C, Koslowski M, Seitz G, Pfreundschuh M (1998)
Identification of a meiosis-specific protein as a member of the class of
cancer/testis antigens. Proc Natl Acad Sci USA 95: 5211–5216
Vidaeus CM, von Kapp-Herr C, Golden WL, Eddy RL, Shows TB, Herr JC
(1997) Human fertilin beta: identification, characterization, and chro-
mosomal mapping of an ADAM gene family member. Mol Reprod Dev
46: 363–369
Vogel T, Dechend F, Manz E, Jung C, Jakubiczka S, Fehr S, Schmidtke J,
Schnieders F (1997) Organization and expression of bovine TSPY.
Mamm Genome 8: 491–496
Zhang JS, Yang-Feng TL, Muller U, Mohandas TK, de Jong PJ, Lau YF
(1992) Molecular isolation and characterization of an expressed gene
from the human Y chromosome. Hum Mol Genet 1: 717–726
An antibody-eliciting novel CT antigen identified in HCC
Y-H Yin et al
463
British Journal of Cancer (2005) 93(4), 458–463 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s